The in silico approach to drug development just got a taste of validation, thanks to some intriguing new research from University of California, San Francisco. A drug cherry-picked with algorithms has behaved as expected: It’s helped shrink tumors in animal models.
The UCSF researchers have created a computational method to delve through enormous amounts of open-access data to find novel drugs — and also discover new ways to repurpose existing drugs. The work was just published in Nature Communications.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Interestingly, there is evidence that certain cancers may be caused by parasites, certain cancers by fungal infections, etc. Perhaps it is not surprising that anti-parasitics and anti-fungals would be effective in those cases.
Cancer is promoted by low hygiene yes, but it is more encouraged by the gene mutations.